XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Segment Reporting Disclosure | SEGMENT INFORMATION We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Therefore, our results of operations are reported on a consolidated basis consistent with internal management reporting reviewed by our chief operating decision maker, who is our chief executive officer. Enterprise-wide disclosures about product sales, revenues and long-lived assets by geographic area, and revenues from major customers are presented below. Product Sales Our product sales consist of the following (in millions):
|  | Year Ended December 31,
|  | 2017 |  | 2016 |  | 2015
Antiviral products: |  |  |  |  |  |
Harvoni |  | $ | 4,370 |  |  | $ | 9,081 |  |  | $ | 13,864 |
Genvoya |  | 3,674 |  |  | 1,484 |  |  | 45 |
Epclusa |  | 3,510 |  |  | 1,752 |  |  | — |
Truvada |  | 3,134 |  |  | 3,566 |  |  | 3,459 |
Atripla |  | 1,806 |  |  | 2,605 |  |  | 3,134 |
Descovy |  | 1,218 |  |  | 298 |  |  | — |
Stribild |  | 1,053 |  |  | 1,914 |  |  | 1,825 |
Viread |  | 1,046 |  |  | 1,186 |  |  | 1,108 |
Odefsey |  | 1,106 |  |  | 329 |  |  | — |
Complera/Eviplera |  | 966 |  |  | 1,457 |  |  | 1,427 |
Sovaldi |  | 964 |  |  | 4,001 |  |  | 5,276 |
Vosevi |  | 293 |  |  | — |  |  | — |
Other antiviral |  | 196 |  |  | 72 |  |  | 69 |
Total antiviral products |  | 23,336 |  |  | 27,745 |  |  | 30,207 |
Other products: |  |  |  |  |  |
Letairis |  | 887 |  |  | 819 |  |  | 700 |
Ranexa |  | 717 |  |  | 677 |  |  | 588 |
AmBisome |  | 366 |  |  | 356 |  |  | 350 |
Zydelig |  | 149 |  |  | 168 |  |  | 132 |
Other products |  | 207 |  |  | 188 |  |  | 174 |
Total product sales |  | $ | 25,662 |  |  | $ | 29,953 |  |  | $ | 32,151 |
Revenues by Geographic Region The following table summarizes total revenues from external customers and collaboration partners by geographic region (in millions). Product sales and product-related contract revenue are attributed to regions based on ship-to location. Royalty and non-product related contract revenue are attributed to regions based on the location of the collaboration partner.
|  | Year Ended December 31,
|  | 2017 |  | 2016 |  | 2015
Revenues: |  |  |  |  |  |
United States |  | $ | 18,194 |  |  | $ | 19,354 |  |  | $ | 21,234 |
Europe |  | 5,311 |  |  | 6,365 |  |  | 7,528 |
Other countries |  | 2,602 |  |  | 4,671 |  |  | 3,877 |
Total revenues |  | $ | 26,107 |  |  | $ | 30,390 |  |  | $ | 32,639 |
Long-lived Assets The net book value of our property, plant and equipment (less office and computer equipment) in the United States was $2.6 billion as of December 31, 2017, $2.2 billion as of December 31, 2016 and $1.8 billion as of December 31, 2015. The corresponding amount in international locations was $520 million as of December 31, 2017, $430 million as of December 31, 2016 and $334 million as of December 31, 2015. All individual international locations accounted for less than ten percent of the total balances. Revenues from Major Customers The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):
|  | Year Ended December 31,
|  | 2017 |  | 2016 |  | 2015
McKesson Corp. |  | 23 | % |  | 22 | % |  | 24 | %
AmerisourceBergen Corp. |  | 20 | % |  | 18 | % |  | 19 | %
Cardinal Health, Inc. |  | 19 | % |  | 16 | % |  | 15 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration